Results 41 to 50 of about 13,121 (228)
Issues on Safety of Long-Acting Muscarinic Antagonist
The prevention of and the controlling of symptoms, reductions in the frequency of exacerbations, and disease severity are central to the pharmacologic therapy of chronic obstructive pulmonary disease (COPD). COPD patients are inclined to be older, have more comorbidities, and use polypharmacy as a result.
Yang Deok Lee, Yongseon Cho, Min Soo Han
openaire +1 more source
Differing time dependencies of object recognition memory impairments produced by nicotinic and muscarinic cholinergic antagonism in perirhinal cortex [PDF]
The roles of muscarinic and nicotinic cholinergic receptors in perirhinal cortex in object recognition memory were compared. Rats' discrimination of a novel object preference test (NOP) test was measured after either systemic or local infusion into the ...
Brown, MW +27 more
core +1 more source
Revefenacin, a long-acting muscarinic receptor antagonist was approved by US Food and Drug Administration in November 2018 for the maintenance treatment of patients with Chronic Obstructive Pulmonary Disease (COPD).
Bhuvana K
doaj +1 more source
Background Methacholine dose-response curves illustrate pharmacologic bronchoprotection against methacholine-induced airway hyperresponsiveness and can be used to quantitate changes in airway sensitivity (position), reactivity (slope), and maximal ...
Christianne M. Blais +2 more
doaj +1 more source
Supplemental Material for The efficacy and safety of additional treatment with short-acting muscarinic antagonist combined with long-acting beta-2 agonist in stable patients with chronic obstructive pulmonary disease: A systematic review and meta ...
Shigeo Muro (152399) +7 more
core +1 more source
Might It Be Appropriate to Anticipate the Use of Long-Acting Muscarinic Antagonists in Asthma? [PDF]
a growing number of clinical trials are documenting that adding a long-acting muscarinic antagonist (LAMA) to established asthma treatment with an inhaled corticosteroid (ICS) and a long-acting beta(2)-agonist (LABA) is a treatment option that improves ...
Matera M. G., Rogliani P., Cazzola M.
core +2 more sources
Normalisation of airflow limitation in asthma: Post‐hoc analyses of TRIMARAN and TRIGGER
Background In asthma, persistent airflow limitation (PAL) is associated with poorer control, lung function decline and exacerbations. Using post‐hoc analyses we evaluated: the relationship between post‐salbutamol PAL at screening, airflow limitation (AL)
Alberto Papi +5 more
doaj +1 more source
Background Muscarinic-receptor antagonists and β-adrenoceptor agonists are used, alone or in combination, as first-line treatment for chronic obstructive pulmonary disease.
Michele Baroffio +2 more
doaj +1 more source
The action spectrum of a tailored azobenzene is shifted toward bio‐optical window through the chemical modification of its singlet and triplet energy levels. Consequently, the bidirectional photo‐switching of azobenzene in physiological conditions is achieved when excited by red and far‐red light, which offers greater tissue penetration.
Mila Miroshnichenko +11 more
wiley +1 more source
Making Sweat Measurable: Induction, Sampling, and Refreshment in Wearable Biofluid Sensing
Wearable sweat sensing relies not only on chemical detection but also on controlled biofluid management. This Review integrates sweat physiology, induction strategies, and microfluidic sampling architectures, demonstrating how flux, transport, and refreshment shape measurement reliability.
Soyoung Shin, Wei Gao
wiley +1 more source

